Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Cash from Operations (2016 - 2017)

Tenax Therapeutics' Cash from Operations history spans 8 years, with the latest figure at 1282071.0 for Q4 2017.

  • For Q4 2017, Cash from Operations rose 58.71% year-over-year to 1282071.0; the TTM value through Dec 2017 reached 12140517.0, up 23.51%, while the annual FY2025 figure was 35800000.0, 141.71% down from the prior year.
  • Cash from Operations for Q4 2017 was 1282071.0 at Tenax Therapeutics, down from 1225932.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1225932.0 in Q3 2017 and bottomed at 60798203.0 in Q4 2013.
  • The 5-year median for Cash from Operations is 3226557.0 (2015), against an average of 9572130.94.
  • The largest annual shift saw Cash from Operations tumbled 2353.0% in 2013 before it surged 95.21% in 2014.
  • A 5-year view of Cash from Operations shows it stood at 60798203.0 in 2013, then soared by 95.21% to 2912448.0 in 2014, then crashed by 31.95% to 3842975.0 in 2015, then grew by 19.2% to 3105069.0 in 2016, then soared by 58.71% to 1282071.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Cash from Operations are 1282071.0 (Q4 2017), 1225932.0 (Q3 2017), and 5595218.0 (Q2 2017).